NewsBriefs BUTTONS


Study Finds that HIV Prevention Programs for Injection Drug Users Must be Tailored to Local Needs

AIDS/NEEDLE EXCHANGE

January 1995

Researchers at the Centers for Disease Control (CDC) have found that the behaviors and the drug-of-choice of injection drug users differ so much from location to location that programs designed to curb the spread of HIV must be tailored to the local conditions to be effective (Theresa Diaz, MD, et.al., "The Types of Drugs Used by HIV-Infected Injection Drug Users in a Multistate Surveillance Project: Implications for Intervention," American Journal of Public Health, Dec. 1994, p. 1971-1975).

The study looked at a sample of 1147 HIV-infected injection drug users in ten locations (data collected in the CDC HIV/AIDS Surveillance Project). 72% of the people surveyed injected a drug other than heroin. Their drug of choice, however, varied greatly from place to place:

Primary Drug Injected by Persons with HIV/AIDS
Who Have Ever Injected Drugs,
by State or City of Residence
(Table 2 of the study)
    Drug Type (%)
  Number Cocaine Heroin Speedball Amphetamines Other
Florida 263 37 11 46 3 3
Denver 157 46 19 2 31 3
Detroit 145 1 94 4 1 1
Atlanta 119 56 20 9 9 5
Arizona 112 44 15 9 25 7
Los Angeles 90 25 25 14 23 13
Connecticut 89 30 48 22 0 0
Washington (state) 85 24 12 4 56 3
South Carolina 42 64 12 10 14 0
Delaware 40 55 23 12 8 3

Total Sample

1142 35 28 17 16 3

Further, 75% of subjects reported using more than one type of drug and 85% reported using drugs that were not injected.

The study found that heroin-injecting drug users were 72% more likely to receive treatment than users of other drugs. Thus, the authors write, methadone maintenance programs, while effective for heroin addicts, may not address the problem in a particular locale.

"Such distinctions emphasize the importance of evaluating local drug use patterns for the appropriate planning of drug treatment services to decrease the spread of HIV," the authors write. "These efforts will require increased provision of drug abuse treatment programs that go beyond methadone, address polysubstance abuse, and adapt to local correlates of the primary drug used."